Skip to main content

Table 1 Participant characteristics

From: TNF blockade contributes to restore lipid oxidation during exercise in children with juvenile idiopathic arthritis

  JIA with TNF-α blockade JIA without TNF-α blockade Healthy controls p
n 15 15 15  
Sex (n; Male/Female) 2/13 2/13 2/13  
Age (years) mean ± SD 13.5 ± 2.2 13.6 ± 2.8 13.7 ± 2.7 0.91
Tanner stage (n; I–II / III–IV) 4/11 4/11 4/11  
Body mass (kg) mean ± SD 49.3 ± 16.3 46.0 ± 13.5 48.9 ± 13.5 0.78
Height (cm) mean ± SD 155.8 ± 15.5 155.5 ± 14.6 154.9 ± 13.2 0.98
BMI (kg/m2) mean ± SD 19.6 ± 4.1 18.6 ± 3.0 20.0 ± 3.4 0.49
JIA subtype (n)    
 oJIA 3 7  
 pJIA RF− 7 4  
 pJIA RF+ 2 1  
 ERA 2 1  
 Psoriatic 1 1  
 Undifferentiated 0 1  
Disease duration (months) mean ± SD 48.1 ± 31.6 46.7 ± 34.1 0.61
Disease activity a (n)    
 Active 4 b 4 c 0.66
 Inactive 11 11
DMARDs (n)    
 NSAIDs 1 4  
 MTX 8 8  
 TNF-α blockade 15 0  
 Adalimumab 3 0  
 Etanercept 10 0  
 Infliximab 2 0  
IPAQ score (n)
 Low level of activity 8 6 5 0.69
 Moderate level of activity 3 5 7
 High level of activity 4 4 3
VO2peak (ml/min) mean ± SD 1568.8 ± 670.9 1464.9 ± 445.3 1637.3 ± 579.9 0.76
VO2peak/body mass (ml/kg/min) mean ± SD 33.0 ± 9.9 32.6 ± 6.0 33.7 ± 8.0 0.83
Rest metabolism (kcal/day) mean ± SD 1467.2 ± 427.6 1431.7 ± 423.7 1767.6 ± 622.4 0.14
  1. JIA juvenile idiopathic arthritis, oJIA oligoarticular JIA, pJIA RF− rheumatoid factor-negative (RF−) polyarticular JIA, pJIA RF+ rheumatoid factor-positive (RF+) polyarticular JIA, ERA enthesitis-related arthritis, psoriatic psoriatic JIA, DMARDs disease-modifying antirheumatic drugs, MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory drugs, IPAQ International Physical Activity Questionnaire. a according to Wallace et al. 2011; b 1 pJIA RF-, 1 pJIA RF+, 1 psoriatic, 1 ERA; c 2 oJIA, pJIA RF-, 1 pJIA RF+